Deals
Takeda Clears Hurdle for $62 Billion Shire Deal
- Approval gives boost to CEO’s efforts to win over shareholders
- Acquisition likely faces tougher antitrust scrutiny in Europe
Photographer: Chris Ratcliffe/Bloomberg
This article is for subscribers only.
Takeda Pharmaceutical Co. cleared a hurdle for its $62 billion acquisition of Shire Plc, receiving unconditional approval from the U.S. Federal Trade Commission two months after sealing its biggest deal ever.
The purchase remains subject to a number of conditions, the Japanese company said in a statement Tuesday, including other regulatory clearances and approval by shareholders of both companies.